Trial Profile
Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 20 Mar 2024 Status changed from active, no longer recruiting to completed.
- 09 Feb 2024 This trial has been completed in Czechia (End Date: 12 Oct 2023), according to European Clinical Trials Database record.
- 19 Dec 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.